Docetaxel-induced hand foot syndrome: “No dose is a safe dose”

Jain, Ankit; Dubashi, Biswajit

doi:10.4103/0976-500X.95534

Case ReportArchivesVol. 3 | Issue 2 | 2012 | pp. 200–201Open Access

Docetaxel-induced hand foot syndrome: “No dose is a safe dose”

¹^*,
¹

¹Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 6, India Case Report.

Correspondence: Ankit Jain
Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 6, India Case Report.

Published: Jan 1, 2012

DOI: https://doi.org/10.4103/0976-500X.95534
Article URL: https://www.jpharmacol.com/article/j-pharmacol-pharmacother-3-2-200
PDF URL: https://www.jpharmacol.com/article/j-pharmacol-pharmacother-3-2-200.pdf

Abstract

Docetaxel is an important chemotherapeutic agent used in the management of many solid tumors. The most important side effect of this drug is myelosupression. We report a case of carcinoma breast that developed severe hand-foot syndrome at 75 mg/m2 doses of docetaxel. The exact mechanism of this side effect in not known. All the physicians using this drug must be aware of this side effect.

Keywords

Subject

Readers Also Viewed

Review Article

Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review

Mohammad Akbar Hossain

Jan 1, 2026

Review Article

Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions

Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei

Jan 1, 2025

Original Research Article

Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models

Annisa Fatharani, Ali Alsayegh

Jan 1, 2026